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Abstract
BACKGROUND: There is limited information on the patterns and trends of contraceptive use 
among women living with HIV, compared with noninfected women in the United States. Further, 
little is known about whether antiretroviral therapy correlates with contraceptive use. Such 
information is needed to help identify potential gaps in care and to enhance unintended pregnancy 
prevention efforts.
OBJECTIVE: We sought to compare contraceptive method use among HIV-infected and 
noninfected privately insured women in the United States, and to evaluate the association between 
antiretroviral therapy use and contraceptive method use.
STUDY DESIGN: We used a large US nationwide health care claims database to identify girls 
and women ages 15–44 years with prescription drug coverage. We used diagnosis, procedure, and 
National Drug Codes to assess female sterilization and reversible prescription contraception use in 
2008 and 2014 among women continuously enrolled in the database during 2003 through 2008 or 
2009 through 2014, respectively. Women with no codes were classified as using no method; these 
may have included women using nonprescription methods, such as condoms. We calculated 
prevalence of contraceptive use by HIV infection status, and by use of antiretroviral therapy 
among those with HIV. We used multivariable polytomous logistic regression to calculate 
unadjusted and adjusted odds ratios and 95% confidence intervals for female sterilization, long-
acting reversible contraception, and short-acting hormonal contraception compared to no method.
RESULTS: While contraceptive use increased among HIV-infected and noninfected women from 
2008 through 2014, in both years, a lower proportion of HIV-infected women used prescription 
contraceptive methods (2008: 17.5%; 2014: 28.9%, compared with noninfected women (2008: 
28.8%; 2014: 39.8%, P < .001 for both). Controlling for demographics, chronic medical 
conditions, pregnancy history, and cohort year, HIV-infected women compared to HIV-noninfected 
women had lower odds of using long-acting reversible contraception (adjusted odds ratio, 0.67; 
95% confidence interval, 0.52–0.86 compared to no method) or short-acting hormonal 
contraception method (adjusted odds ratio, 0.59; 95% confidence interval, 0.50–0.70 compared to 
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no method). In 2014, HIV-infected women using antiretroviral therapy were significantly more 
likely to use no method (76.8% vs 64.1%), and significantly less likely to use short-acting 
hormonal contraception (11.0% vs 22.7%) compared to HIV-infected women not using 
antiretroviral therapy. Those receiving antiretroviral therapy had lower odds of using short-acting 
hormonal contraception compared to no method (adjusted odds ratio, 0.45; 95% confidence 
interval, 0.32–0.63). There was no significant difference in female sterilization by HIV status or 
antiretroviral therapy use.
CONCLUSION: Despite the safety of reversible contraceptives for women with HIV, use of 
prescription contraception continues to be lower among privately insured HIV-infected women 
compared to noninfected women, particularly among those receiving antiretroviral therapy.
Keywords
antiretroviral therapy; contraception; HIV
Introduction
It is estimated that as of 2014, 25% of people living with HIV in the United States were 
women.1 Access to accurate contraceptive method information and a full range of effective 
options is important for HIV-infected women not only to prevent unintended pregnancy, but 
also to prevent vertical transmission of HIV. According to the US Medical Eligibility 
Criteria for Contraceptive Use (MEC),2 all contraceptive methods are considered safe or 
generally safe for use by HIV-infected women. Further, concern regarding drug interactions 
may limit providers from recommending hormonal contraceptives. In contrast, the most 
recent US MEC guidelines do not recommend limiting any contraceptives based on 
antiretroviral therapy (ART) use. An exception to this recommendation is the infrequently 
prescribed protease inhibitor fosamprenavir. For women using fosamprenavir, current 
recommendations state that the risks of combined hormonal contraception outweigh the 
benefits.3 HIV-infected individuals are encouraged by their providers to use condoms to 
prevent HIV transmission to uninfected partners. While there is increasing use of effective 
prescription contraceptive methods in the general population,2 specifically long-acting 
reversible contraceptives (LARC) (which include intrauterine devices [IUDs] and implants), 
some data suggested that women with HIV are more likely to use less effective contraceptive 
options such as condoms.4 High rates of female sterilization2 and reduced overall pregnancy 
rates during early stages of the HIV epidemic may not have continued. Among women with 
HIV, ART use has increased due to efforts to improve access to testing and ART and 
guidelines suggesting earlier initiation of ART.5 Due to increasing ART use, improved 
health outcomes, and the lower perceived HIV transmissibility associated with viral load 
suppression, the trends in contraceptive use among HIV-infected women may be becoming 
more similar to those among noninfected women.
Our aim was to evaluate prescription contraceptive use among HIV-infected women 
compared to noninfected women in the United States in 2008 and 2014. Specifically, we 
aimed to examine differences in the pattern of prescription contraceptive methods based on 
HIV infection status and to explore the impact of ART use on contraceptive method use. 
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This information will provide contemporary contraceptive trends and explore the 
associations between HIV and ART use and contraceptive practice patterns.
Materials and Methods
We analyzed data from the Truven Health MarketScan Commercial Claims and Encounters 
databases. These databases consist of a large convenience sample of individuals with 
employer-based health insurance and include individual-level health care claims information 
from employer health plans with both inpatient and outpatient diagnoses and procedure 
codes and links to filled outpatient prescription drug claims. All claims for a particular 
individual can be linked even if the employer changes insurance plans, but may not be linked 
if the individual changes employment. The average number of female enrollees in the 
database is approximately 11.4 million per year in years 2003 through 2008 and 
approximately 24 million per year in years 2009 through 2014. These databases undergo 
quality assessments to maintain validity of the data.6 As the databases are deidentified, the 
institutional review board of the Centers for Disease Control and Prevention determined that 
this was not human subjects research.
We evaluated 2 cohorts of women to determine contraceptive use for index years 2008 and 
2014. For each index year, we included women continuously enrolled for 5 years prior, to 
account for previously initiated LARC methods or sterilization. Specifically, for 2008, we 
included women continuously enrolled from 2003 through 2008; for 2014, we included 
women continuously enrolled from 2009 through 2014. Girls and women were included if 
they were ages 15–44 years and had health plans with prescription drug coverage. We 
excluded women who had a prior diagnostic or procedure code for hysterectomy from the 
analysis of contraceptive method use. Notably any women with a hysterectomy code 
identified in the 2003 through 2008 period, thus excluded in 2008, were also excluded from 
the 2014 cohort. To identify the exposures, outcomes, and covariates, such as pregnancy and 
chronic medical conditions, we used International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) and Current Procedural Terminology codes 
(see Appendix for specific coding for conditions and medications).
Our primary exposures of interest were HIV infection status and ART use (among HIV-
infected women). HIV infection was defined by meeting 1 of the following 4 criteria: (1) 2 
outpatient visits with HIV diagnosis codes separated by ≥30 days; (2) 1 outpatient diagnosis 
code for HIV and at least 1 antiretroviral drug (see list in Appendix of ART medications 
considered; medications typically used for preexposure or postexposure prophylaxis without 
concomitant other ART medication were excluded); (3) 2 pharmacy charges for at least 1 
ART separated by ≥30 days; or (4) 1 inpatient stay with HIV diagnosis code. We defined 
HIV-infected women as ART users if they filled at least 1 prescription for ART (drug names 
listed in Appendix) during the 6 years of the cohort.
Our primary outcome of interest was female sterilization or reversible prescription 
contraceptive use during the index year. This was identified from inpatient, outpatient, and 
pharmaceutical databases using ICD-9-CM diagnosis and procedure codes, Healthcare 
Common Procedure Coding System supply codes, Current Procedural Terminology codes, 
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and the US Food and Drug Administration National Drug Codes. We considered 
prescriptions to be a proxy measure for actual use. Contraceptive methods examined 
included female sterilization and reversible prescription methods such as IUDs, implants, 
injectables, pills, patches, and rings. A woman was identified as sterilized if a sterilization 
code was present in the inpatient or outpatient databases in the 6 years of the cohort. A 
woman was considered to be an IUD user during the index year if the method was placed 
based on a procedure code or supply code from the inpatient or outpatient databases during 
that index year or within the 5 years prior without a removal code noted. A woman was 
considered to be an implant user during the index year if the method was placed based on a 
procedure code or supply code from the inpatient or outpatient databases during that index 
year or within 3 years prior without a removal code noted. We searched for codes in the 
index year indicating injectable, pill, patch, or ring use. These methods needed to be 
identified at least once during the index year to be considered as use during that year. 
Injectable use was identified from inpatient and outpatient claims if there was a depot 
medroxyprogesterone acetate supply code or a family planning encounter diagnosis code 
coupled with a generic injection procedure code. Use of oral contraceptive pills (including 
combined and progestin-only pills), combination hormonal patches, or combination vaginal 
rings was identified by National Drug Codes in the pharmaceutical databases. If there were 
no sterilization or contraceptive codes identified, the individual was classified as using no 
method. Individuals classified as using no method may have been using nonprescription 
methods such as condoms. We used a method of hierarchal classification to determine the 
most effective method of contraceptive used similar to one previously described.7 We 
collapsed the methods into 4 categories to evaluate trends in method use: (1) female 
sterilization; (2) LARC method (IUDs and implants); (3) short-acting hormonal 
contraception (SAHC), including shorter-acting prescription methods (injectable, pills, 
patch, or ring); and (4) no prescription method.
For covariates, we included age (3 categories: 15–24, 25–35, 36–44 years), region in the 
United States (defined as the following 5 categories by Truven Health: Northeast, North 
Central, South, West, unknown), chronic medical condition, and pregnancy. We identified 
women as having a chronic medical condition if they had 1 of the following conditions that 
were identified by the US MEC as: (1) conditions with increased health risks from an 
intended pregnancy; or (2) conditions for which certain contraceptives are considered unsafe 
or the risks outweigh the benefits. 6 The 22 chronic conditions included: diabetes, 
hypertension, epilepsy, breast cancer, endometrial cancer, ovarian cancer, tuberculosis, sickle 
cell disease, systemic lupus erythematosus, cirrhosis, thrombogenic mutations, 
schistosomiasis with fibrosis of liver, liver cancer, gestational trophoblastic disease, 
ischemic, heart disease, valvular heart disease, stroke, transplant, peripartum 
cardiomyopathy, bariatric surgery, and migraines (without or without aura).We used ICD-9-
CM diagnosis and procedural codes to identify these conditions. Utilizing a methodology 
similar to one previously published,7–9 we classified women as having a medical condition 
during the index year if related codes were present during 5 years prior to that year. To 
improve specificity and avoid overdiagnosis, we considered an individual as having the 
condition if there were 2 outpatient codes present at least 30 days apart (with the exception 
of migraines for which only 1 outpatient code was needed) or 1 inpatient code. Pregnancies 
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(either current pregnancy or recent pregnancy with a pregnancy outcome) were identified if 
they had a diagnosis or procedure code for 1 of the following outcomes during the index 
year: any pregnancy, delivery, ectopic, molar pregnancy, or abortion (spontaneous or 
induced).
All statistical analyses were performed with SAS (Version 9.3; SAS Institute Inc, Cary, NC) 
or SUDAAN (Version 11.0.0, RTI International, Research Triange Park, NC). We generated 
descriptive statistics for contraceptive use and covariates with corresponding numbers and 
percentages. In cases where cell counts were <5, the numbers and corresponding 
percentages were not reported to protect individual-level data. If it was possible to calculate 
one of the suppressed cells with counts<5 from the other cells of that variable, a second cell 
was also not reported. In all statistical analyses, a random effect (identifying individual 
women) was used to account for women in both the 2008 and 2014 cohorts. Bivariate 
analyses were performed with Fisher exact test or χ2 test with a P value ≤.001 considered 
statistically significant based on the Holm-Bonferroni method for multiple comparisons. We 
performed multivariable polytomous logistic regression to generate unadjusted and adjusted 
odds ratios (aOR) with 95% confidence intervals (CIs) for sterilization, LARC, and SAHC 
compared to no prescription method use among all women and a separate multivariable 
polytomous logistic regression restricted to HIV-infected women to examine ART use. 
Covariates significant at the .05 level were maintained in the multivariable polytomous 
logistic regression models. Contraceptive use was examined separately for each cohort (2008 
or 2014). For the multivariable polymtomous logistic regression, we included both the 2008 
and 2014 cohorts and included year in the model as a covariate. Estimates for cohort year 
are presented from the model including HIV status.
Results
In 2008, 499,197 women were included, with 268 (0.05%) meeting our criteria for being 
HIV-infected. In 2014, 1,083,864 women were included with 917 (0.08%) meeting our 
criteria for being HIV-infected (Table 1). There were 90,916 women represented in both 
cohorts. In both 2008 and 2014, the HIV-infected women were older and had more chronic 
medical conditions than noninfected women with 39.2% and 42.5% of the HIV-infected 
women having a chronic medical condition in 2008 and 2014, respectively. Among HIV-
infected women, there was no significant increase in the percent of pregnancies from 2008 
(5.6%) through 2014 (7.5%) There were also no significant differences in the percent of 
pregnancies between HIV-infected and noninfected women in either year.
Overall, the majority of women did not use female sterilization or a prescription 
contraceptive (Table 2). However, significantly more HIV-infected women in our cohort 
were not using sterilization or a prescription method in 2008 (82.5%) and 2014 (71.1%) 
compared to noninfected women (71.2% in 2008 and 60.2% in 2014). LARC method use 
did not significantly differ between infected and noninfected women, and both groups 
experienced a significant increase from 2008 through 2014. SAHC use was significantly 
lower among HIV-infected women in both 2008 (10.4%) and 2014 (16.2%) compared to 
noninfected women (22.0% in 2008 and 28.6% in 2014).
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Among the HIV-infected women, 170 (73.4%) and 508 (67.2%) were ART users in 2008 
and 2014, respectively. ART use significantly varied by region in both 2008 and 2014, with 
increased proportion of HIV-infected women in the South using ART (data not shown). In 
2008, among HIV-infected women, there were no significant differences in contraceptive 
method use by ART use (Table 3). In 2014 there was significantly lower proportion of 
women using a prescription method among HIV-infected women on ART compared to HIV-
infected women not on ART (23.2% vs 35.9%), with a lower proportion of women on ART 
using SAHC methods compared to women not on ART (11.0% vs 22.7% for ART and 
nonART, respectively). There was increased LARC use among ART users from 2008 
through 2014. In both the ART and no ART groups, there were more women using 
prescription method in 2014 compared to 2008, although this difference was not statistically 
significant.
Results of the multivariable polyto-mous regression models evaluating contraceptive use are 
reported in Table 4. There were lower odds of LARC method (aOR, 0.67; 95% CI, 0.52–
0.86 vs no prescription method) and SAHC method use (aOR, 0.59; 95% CI, 50–0.70 vs no 
prescription method) among HIV-infected women compared to noninfected women when 
controlling for covariates and cohort year. Although among HIV-infected women, the 
adjusted odds of LARC use and sterilization did not significantly differ by ART status, there 
were significantly lower adjusted odds of SAHC method use among ART users compared to 
non-ART users. Overall, there was an increase in sterilization, LARC, and SAHC method 
compared to no method use from 2008 through 2014.
Comment
Our study evaluating a large national database of privately insured women highlights the 
persistent discrepancy in contraceptive use for HIV-infected women compared to 
noninfected women in the United States. While prior studies demonstrated an encouraging 
increase in the use of more effective LARC contraceptives10 among noninfected women, our 
report also suggests this trend maybe occurring among HIV-infected women, a finding that 
differs from prior reports.2 Despite this improvement in overall effective contraceptive use, 
our results show that reliance on no prescription method or female sterilization is more 
common among women with HIV compared with uninfected women. Prior research 
similarly found that HIV-infected women often rely on nonprescription contraceptive 
methods, such as condoms.11 As the pregnancy rates with typical condom usage are as high 
as 15% in the first year of use,12 current recommendations emphasize the need for dual 
protection, simultaneous use of a second more effective method of contraception 
(sterilization, LARC, or SAHC) in addition to condoms for sexually transmitted infection 
and HIV prevention. Our data indicate that the reliance on lower efficacy nonprescription 
contraceptive methods or no method persists despite these current dual-method 
recommendations. Given the high rates of unintended pregnancy in the United States, which 
are associated with negative health consequences, along with risks associated with 
pregnancy among HIV-infected women, efforts should be directed at increasing use of 
effective contraception beyond condoms alone among HIV-infected women as well.13 
Further, since those in our study with HIV are older with more chronic medical conditions, 
contraceptive use to reduce the risks associated with unintended pregnancy should be 
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emphasized. A recent study demonstrates that despite decreasing rates of induced abortion 
nationally, such rates among HIV-infected women have remained stable,13 suggesting that 
prevention of unintended pregnancy has not improved overall reproductive outcomes for 
women with HIV.
Our data highlight that those with HIV are about 40% less likely to use SAHC compared to 
noninfected women. Lower use ofthese contraceptives among women with HIV may be 
related to providers’ concerns about the safety of certain methods for women with HIV. 
However, evidence has not demonstrated that hormonal contraceptives are associated with 
HIV disease progression or HIV transmission to uninfected male partners.14
Our findings also highlight that among women with HIV, those using ART have about 50% 
lower odds ofusing SAHC than those not using ART. This may be related to ongoing 
concerns regarding the safety of combining certain hormonal contraceptive methods with 
antiretroviral drugs given concerns for drug-drug interactions reducing the effectiveness of 
either the birth control or ART. However, HIV-infected women should be reassured that 
studies have found few interactions between hormonal contraceptives and antiretroviral 
drugs that limit their use. Even in cases where a drug interaction may exist, studies 
suggested the impact could lead to a reduction in contraceptive but not antiretroviral 
effectiveness.15–17 In these situations, such as the case of efavirenz-based regimens used 
with an etonogestrel or levonorgestrel contraceptive implant, the implant effectiveness is 
often still superior to nonprescription contraceptive alternatives.18 Further, in cases where a 
provider may be concerned or unfamiliar with the potential drug-drug interactions, 
alternative forms of effective contraception, such as the nonhormonal IUD, can be 
considered. Health care providers should counsel women about the overall safety of 
contraceptives used in conjunction with ART, present a broad spectrum of contraceptive 
options available to avoid potential drug interactions, and not be hesitant to provide 
hormonal contraception, especially LARC, to women on ART.
We did not find a difference in the rates of sterilization among women with HIV compared 
to noninfected women. This is contrary to reports from earlier in the HIV epidemic when 
women reportedly felt pressure to undergo sterilization, and, even in cases when sterilization 
was not coerced, many experienced subsequent regret.19 Our findings support an 
encouraging change toward increased reproductive choice for HIV-infected women.
As ART use increases and health status improves, recent data suggest that HIV-infected 
women have desires for children and pregnancy rates similar to noninfected women.20 ART 
users should receive regular clinical care, thus offering numerous opportunities to address 
their contraceptive needs. Unfortunately, family planning is often absent from the current 
HIV clinical care paradigm. This integration of services is essential if we hope to adequately 
address the robust reproductive health needs of women living with HIV. Efforts must focus 
on understanding reproductive health needs of this cohort and providing targeted family 
planning options within an integrated care framework. Our study has several strengths as 
well as some limitations. With use of this large claims data set, we are able to evaluate a 
nationwide sample of privately insured women living with HIV compared to noninfected 
women as well as evaluate the change in patterns over time. Further, by controlling for other 
Haddad et al. Page 7
Am J Obstet Gynecol. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
medical conditions that may influence contraceptive prescription patterns, we are able to 
more specifically determine the impact of HIV on contraceptive use. While our data are 
representative of a nationwide privately insured population, they may not be generalizable to 
Medicaid or uninsured populations. As a significant proportion of women with HIV rely on 
Medicaid or are uninsured, we may not be able to extrapolate these findings to all HIV-
infected women. However, it is notable that women continuously enrolled in these health 
care plans should have similar access to contraceptives and thus any differences detected 
likely reflect true practice pattern differences within the cohort of women who are insured. 
While we demonstrate an overall improvement in contraceptive use over time, the impact of 
the Affordable Care Act, passed in 2010, on access to contraception may account for some 
of these observed patterns. The small number of HIV-infected women, particularly ART 
users, may have reduced our power to detect differences between groups. As with any 
administrative database, there are inherent risks of misclassification. We aimed to reduce 
misclassification by using more conservative definitions for defining diagnoses, including 2 
outpatient visits, rather than 1. Further, while we aimed to capture contraceptive and surgical 
procedures for individuals over a continuous time frame of 6 years for each cohort, we may 
have not captured sterilization procedures or IUD insertions performed outside of the study 
interval. Additionally, prescriptions may not reflect actual use of the contraceptive. This is 
particularly important for user-dependent methods such as combined hormonal contraceptive 
pills, where individuals may incorrectly, infrequently, or never use the method prescribed. 
Women classified as non-users may have included those with IUD insertion, sterilizations, or 
hysterectomy before 2004; women relying on male sterilization or using nonprescription 
methods (barrier methods or fertility awareness-based methods); or women who were 
pregnant, trying to become pregnant, not sexually active, or otherwise not at risk for 
unintended pregnancy. Lastly, we captured only prescription and surgical contraceptive 
methods and cannot specifically comment on the use of nonprescription methods, such as 
condoms. This underscores that certain women may be relying on no method or condom use 
alone, rather than a more effective prescription methods of birth control. Providers need to 
counsel patients on the use of more highly effective prescription contraceptive methods, 
beyond condom use. For HIV-infected individuals specifically, providers must go beyond 
condom promotion to emphasize dual-method use with combining condoms, for HIV and 
sexually transmitted infection prevention, along with prescription contraceptive use, for 
pregnancy prevention.
In conclusion, our data highlight a persistent gap in effective contraceptive use among 
women with HIV in the United States compared to HIV-uninfected women. We should aim 
to better understand the reasons for lower use of LARC and SAHC methods and further 
promote effective contraceptives. Future efforts should focus on increasing dual-method 
contraceptive use while educating patients and providers regarding potential misconceptions 
that could limit contraceptive use. Our findings emphasize the importance of understanding 
the reproductive health needs of women living with HIV and providing targeted family 
planning options as part of routine HIV care.
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Appendix
List of conditions and procedures by International Classification of Diseases, Ninth 
Revision, Clinical Modification diagnostic and procedure; Current Procedural Terminology; 
Healthcare Common Procedure Coding System; and diagnosis-related group codes
Condition/procedures
ICD-9-CM diagnostic and 
procedure codes CPT, HCPC codes DRG codes
HIV 042.X, 043.X, 044.X, V08.X, 
079.53, 279.10, 279.19, 795.71, 
795.8
Hysterectomy 68.3, 68.4, 68.5, 68.6, 68.7, 
68.8, 68.9
45126, 51597, 51925, 58150, 
58152, 58180, 58200, 58210, 
58240, 58260, 58262, 58263, 
58267, 58270, 58275, 58280, 
58285, 58290, 58291, 58292, 
58293, 58294, 58541, 58542, 
58543, 58544, 58548, 58550, 
58552, 58553, 58554, 58570, 
58571, 58572, 58573, 58951, 
58953, 58954, 58956, 59100, 
59135, 59525
Pregnancy (current pregnancy 
or recent pregnancy with 
pregnancy outcome)
63X.X, 64X.X, 65X.X, 651.X, 
66X.X, 67X.X, 69.X, 72.X, 
73.22, 73.59, 73.6, 74.X, 75.X, 
V27.X, V91.X
59409, 59514, 59612, 59620, 
59840, 59841, 59850, 59851, 
59852, 59855, 59856, 59857
Before 2007: 
370–375, 378, 
380, 381 
≥2007: 765, 
766, 767, 768, 
774, 775, 770, 
777, 779
Medical conditions: diabetes, 
hypertension, epilepsy, breast 
cancer, endometrial cancer, 
ovarian cancer, tuberculosis, 
sickle cell disease, systemic 
lupus erythematosus, cirrhosis, 
thrombogenic mutations, 
schistosomiasis with fibrosis of 
liver, liver cancer, gestational 
trophoblastic disease, ischemic 
heart disease, valvular heart 
disease, stroke, transplantation, 
peripartum cardiomyopathy, 
bariatric surgery, migraines 
with aura and without aura
010.X, 011.X, 012.X, 013.X, 
014.X, 015.X, 016.X, 017.X, 
018.X, 120.X, 155.X, 174.X, 
182.X, 183.X, 197.7, 198.6, 
198.81, 199.2, 230.8, 
233.0,233.2, 235.3, 236.2, 
238.3, 238.77,239.3, 250.X, 
282.6X, 289.81, 345.0, 345.1, 
345.2, 345.3, 345.4, 345.5, 
345.7, 345.8, 345.9, 346.0X, 
346.1X, 346.2X, 346.3X, 
346.4X, 346.5X, 346.6X, 
346.7X, 346.8X, 346.9X, 394.X, 
395.X, 396.X, 401.X, 402.X, 
403.X, 404.X, 405.X, 410.X, 
411.X, 412.X, 413.X, 414.X, 
430.X, 431.X, 432.X, 433.X, 
434.X, 435.X, 436.X, 437.X, 
571.2, 571.5, 571.6, 630.X, 
674.5X, 710.0, 996.8X, E87.80, 
V42.X, V45.86, V58.44
43644, 43645, 43770, 43771, 
43773, 43842, 43843, 43845, 
43846, 43847, 43848, 43886, 
43887, 43888
Sterilization V25.2, 66.2, 66.3 58565, 58579, 58600, 58605, 
58611, 58615, 58670, 58671, 
A4264
IUD Insertion: V25.11, V25.13, 69.7
Removal: V25.12, 97.71
Insertion: 58300, J7300, 
J7302
Removal: 58301
Implant Insertion: V25.5 Insertion: 
11975, 11977, 
J7307, J7306, 
S0180:
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Condition/procedures
ICD-9-CM diagnostic and 
procedure codes CPT, HCPC codes DRG codes
Removal: 
11976
Injectable contraception V25.02, V25.03, V25.04, 
V25.09, V25.40, V25.49, V25.8, 
V25.9
J1051, J1055, J1056, 96372 
(≥2009), 90772 (before 2009)
CPT, Current Procedural Terminology; DRG, diagnosis-related group; HCPC, Healthcare Common Procedure Coding 
System; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; IUD, intrauterine 
device.
List of medications
Medications Generic product identification National Drug Code Drug names
Contraceptive ring 123340
Contraceptive patch 119146, 128775, 131135
Contraceptive pills 101027, 101489, 101490, 102153, 102759, 
102760, 102761, 102762, 102765, 102768, 
102769, 102772, 102775, 102776, 108159, 
108160, 108835, 109055, 109514, 109630, 
109788, 109879, 110119, 112742, 113364, 
113365, 113426, 113486, 114219, 114407, 
114634, 115052, 122790, 122792, 122793, 
122794, 122795, 122796, 122799, 122800, 
122801, 122802, 122803, 122804, 122806, 
122807, 122809, 122810, 122812, 122870, 
122908, 123025, 123044, 123058, 123545, 
123546, 123548, 123638, 123644, 123771, 
123773, 123779, 124134, 124392, 124749, 
125060, 125086, 125218, 125234, 125375, 
125376, 125561, 125789, 125887, 125947, 
126318, 127463, 128230, 128236, 128255, 
128449, 128593, 128656, 128732, 128748, 
128839, 128856, 129061, 129213, 129929, 
130110, 130644, 130698, 130775, 131061, 
131315
00008005603, 
00008007802, 
00008007803, 
00014005106, 
00014008158, 
00014008184, 
00014015142, 
00014015160, 
00014016156, 
00014016184, 
00014040107, 
00014040108, 
00014040113, 
00014040124, 
00014040160, 
00014040163, 
00014042109, 
00014042114, 
00014042115, 
00025005131, 
00025007113, 
00025008114, 
00025010150, 
00025015113, 
00025016114, 
00025031103, 
00025032103, 
00025033106, 
00025034106, 
00046089410, 
00062135108, 
00062139015, 
00062139115, 
00062176022, 
00062176122, 
00062177022, 
00062177122, 
00071090111, 
00071090146, 
00071090335, 
00071090336, 
00071090411, 
00071090446, 
00071090535, 
00071090536, 
00071090735, 
00071090736, 
00071091336, 
00071091546, 
00071091646, 
00071091736, 
00251341010, 
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Medications Generic product identification National Drug Code Drug names
00251361010, 
00251381010, 
00304205621, 
00304205628, 
00304205721, 
00304205728, 
00304210428, 
00536405544, 
00536405644, 
00536405744, 
17236038528, 
17236046012, 
17236046028, 
42987010213, 
42987010214, 
42987010223, 
42987010224, 
42987010227, 
42987010228, 
42987010312, 
42987010320, 
47202290921, 
47202291028, 
54765003521, 
54765003528, 
99999100026, 
99999100063, 
99999100068, 
99999100084, 
99999200026, 
99999200063, 
99999200068, 
99999200084, 
99999777603, 
99999777604, 
99999777606, 
99999777607
Antiretroviral drugs 104056, 104057, 104058, 104059, 104060, 
104209, 104210, 104211, 104212, 108940, 
109377, 109378, 109407, 109408, 110254, 
110888, 111835, 111837, 112183, 112244, 
113370, 113371, 113372, 113435, 113554, 
113555, 113816, 113847, 113848, 113873, 
114636, 114940, 114941, 116190, 119066, 
123003, 123233, 123234, 123235, 123517, 
123885, 124326, 124601, 124730, 124854, 
125221, 125492, 125992, 126048, 126049, 
126223, 126322, 126431, 126624, 126643, 
126644, 126696, 126996, 127176, 127215, 
127432, 128047, 128681, 128833, 128988, 
129147, 129495, 129496, 129510, 129954, 
130130, 130236, 130480, 130752, 130934, 
130985, 131196, 131352, 131413, 131557, 
131632
Abacavir sulfate, 
abacavir sulfate/
lamivudine, 
abacavir sulfate/
lamivudine/
zidovudine, 
abacavir/
dolutegravir/
lamivudine, 
amprenavir, 
atazanavir sulfate, 
atazanavir/
cobicistat, 
cobicistat/
darunavir, 
cobicistat/
elvitegravir/
emtricitabine/
tenofovir 
disoproxil 
fumarate, 
darunavir 
ethanolate, 
dolutegravir 
sodium, efavirenz, 
efavirenz/
emtricitabine/
tenofovir 
disoproxil 
fumarate, 
elvitegravir, 
emtricitabine/
rilpivirine 
hydrochloride/
tenofovir, 
enfuvirtide, 
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Medications Generic product identification National Drug Code Drug names
etravirine, 
fosamprenavir 
calcium, indinavir 
sulfate, 
lamivudine/
zidovudine, 
lopinavir/ritonavir, 
maraviroc, 
nelfinavir 
mesylate, 
nevirapine, 
raltegravir 
potassium, 
rilpivirine 
hydrochloride, 
ritonavir, 
saquinavir, 
saquinavir 
mesylate, 
stavudine, 
tipranavir, 
zalcitabine, 
zidovudine
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